

CiPA Guidelines

The Comprehensive *in vitro* Proarrhythmia Assay (CiPA) provides guidelines for evaluating a pharmaceutical drug's tendency to induce cardiac arrhythmias, such as Torsade de Pointes (TdP).

Several other ion channels will be similarly investigated to determine their role in inducing cardiac anomalies in the presence of a drug, including hERG, hNaV1.5, hCaV1.2, hKir2.1, and hMink.

Analysis of these parameters *in-vitro* is indeed a more comprehensive approach and will keep potentially dangerous compounds from reaching clinical stages.

AVIVA Biosciences offers screening services for the following human derived ion channels:

ASC1a	KIR2.1	GABA
TRPA1	Kv1.3	Nav1.4
TRPM8	Kv1.5	Nav1.5
Kv11.1	Cav1.2	Nav1.7
Kv4.3	CIC-1	Nav1.8
Kv7.2	CIC-4	

